Epidemiology of Venous Thromboembolism

Sponsors

Lead sponsor: Brigham and Women's Hospital

Source Brigham and Women's Hospital
Brief Summary

To evaluate potentially modifiable lifestyle predictors of venous thromboembolism and their joint associations with biochemical and genetic determinants.

Detailed Description

BACKGROUND:

Venous thromboembolism is a common condition with considerable morbidity and mortality. The disorder has diverse causes including trauma, stasis, drugs, cancer, and genetic factors that contribute to enhanced clotting and coagulation. The study uses existing large-scale population studies to unravel factors responsible for and contributing to venous thromboembolism.

DESIGN NARRATIVE:

The study design is a prospective cohort study of 77,118 persons based on pooling information from four large randomized trials of US health professionals that have collected detailed risk factor information and have used common strategies to prospectively identify and validate cases of venous thromboembolism (VTE). These trials are: Physicians' Health Studies I & II including 29,071 US male physicians, of whom 22,071 have been followed since the initiation of the first trial in 1982; the Women's Health Study including 39,876 female health professionals who will have an average of 10 years of follow-up; and the Women's Antioxidant Cardiovascular Study including 8,171 female health professionals with prevalent cardiovascular disease or at high risk of cardiovascular disease who will have an average of 8 years of follow-up. Archived blood samples were collected from approximately 75 percent of participants at baseline and will be used to assess biochemical and genetic markers of risk including factor V Leiden, the G20210A mutation in the prothrombin gene, hyperhomocysteinemia, and anticardiolipin antibodies. The study will assess the joint association with risk of these markers and potentially modifiable factors including body mass index, hormone replacement therapy, physical activity, and aspirin use. The study population will include over 1,000 incident cases of VTE, including 750 with blood samples.

Overall Status Completed
Start Date July 2002
Completion Date June 2006
Primary Completion Date June 2006
Study Type Observational
Condition
Eligibility

Criteria:

No human subjects are involved. Collected data are used.

Gender: All

Minimum age: N/A

Maximum age: N/A

Healthy volunteers: No

Overall Official
Last Name Affiliation
Robert Glynn Brigham and Women's Hospital
Verification Date

August 2015

Responsible Party

Responsible party type: Principal Investigator

Investigator affiliation: Brigham and Women's Hospital

Investigator full name: Robert James Glynn, PhD

Investigator title: Biostatistician; Professor of Medicine

Has Expanded Access No
Condition Browse
Arm Group

Arm group label: Physicians' Health Study I

Arm group label: Physicians' Health Study II

Arm group label: Women's Health Study

Arm group label: Women's Antioxidant Cardiovascular Health Study

Source: ClinicalTrials.gov